Talk:Aripiprazole - PsychonautWiki

Talk:Aripiprazole

Active discussions
(Redirected from Aripiprazole)
Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: Aripiprazole
Aripiprazole
Aripiprazole.svg
Chemical Nomenclature
Common names Aripiprazole, Abilify
Systematic name 7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Bioavailability 87%[1]
Threshold 1 mg
Light 1 - 5 mg
Common 5 - 15 mg
Strong 15 - 30 mg
Heavy 30 mg +
Duration
Total 72 - 120 hours
Onset 30 - 60 minutes
Come up 3 - 5 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


Aripiprazole (branded as Abilify, Aristada among others) is an atypical antipsychotic approved for the treatment of schizophrenia, psychosis, bipolar disorder, and along with an antidepressant to treat major depressive disorder.

History and culture

Aripiprazole, developed by Otsuka Pharmaceutical and marketed as Abilify among others, was first approved in Japan in 2002 and subsequently in the United States. It was a novel development in the field of atypical antipsychotics, primarily intended for schizophrenia and bipolar disorder treatment. Over time, its use expanded to include treatment of major depressive disorder and irritability in autism spectrum disorders.

Chemistry

Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C23H27Cl2N3O2, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.

Pharmacology

Aripiprazole's primary mechanism involves acting as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, while also serving as an antagonist at serotonin 5-HT2A receptors. This dual action contributes to its efficacy in treating both the positive and negative symptoms of schizophrenia. It also exhibits moderate affinity for histamine, adrenergic, and muscarinic receptors, contributing to some of its side effects.

Subjective effects

 
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Cognitive effects
 


Experience reports

There are a limited number of experience reports for Aripiprazole given its medical usage, but some can be found in the experience index and on external platforms like Erowid.

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Although generally safe at therapeutic doses, Aripiprazole overdose can lead to severe symptoms like seizures, vomiting, and agitation. Long-term use may increase the risk of metabolic syndrome.

Lethal dosage

The lethal dosage of Aripiprazole is not well-established, but it is considered to have a high therapeutic index.

Tolerance and addiction potential

Aripiprazole has a low potential for abuse and addiction. Tolerance development is minimal.

Dangerous interactions

Aripiprazole should not be combined with other substances that depress the central nervous system, such as alcohol, benzodiazepines, or opioids.

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Aripiprazole is a prescription medication in many countries. Its legal status varies, but it is generally regulated and available only with a doctor's prescription.

See also

External links

References

Return to "Aripiprazole" page.